# WisdomTree BioRevolution Fund



## **Fund Overview**

The WisdomTree BioRevolution Fund seeks to track the price and yield performance, before fees and expenses, of the WisdomTree BioRevolution Index.

## Why WDNA?

- Gain targeted exposure to companies that seek to benefit from the revolution in biology focused technologies.
- Use to complement core portfolios with innovative growth megatrends in the biology space.
- Satisfies demand for multi-sector genetics and biotechnology investments with strong growth characteristics.

## All Data As of 03/31/2024

#### **Fund Information**

Ticker Symbol	WDNA
Inception Date	06/03/2021
Gross Expense Ratio	0.45%
Net Expense Ratio	0.45%
Number of Holdings	91
CUSIP	97717Y618
Stock Exchange	Cboe
Bloomberg Index Symbol	WTDNAN
Net Assets (\$mm)	\$2.57

# Performance Average Annual Total Returns as of 03/31/2024

Name	QTR	YTD	1-Year	3-Year	5-Year	10-Year	Since Fund Inception
WDNA NAV Returns	1.72%	1.72%	0.74%	N/A	N/A	N/A	-12.12%
WDNA Market Price Returns	3.14%	3.14%	2.02%	N/A	N/A	N/A	-11.69%
WisdomTree BioRevolution Index	1.69%	1.69%	0.48%	N/A	N/A	N/A	-12.12%
S&P 500 Health Care Index	8.85%	8.85%	16.09%	N/A	N/A	N/A	9.14%
S&P Biotechnology Select Industry Index	6.47%	6.47%	25.67%	N/A	N/A	N/A	-9.62%

Performance of less than one year is cumulative. You cannot invest directly in an index.

Performance is historical and does not guarantee future results. Current performance may be lower or higher than quoted. Investment returns and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost. Performance data for the most recent month-end is available at wisdomtree.com/investments.

WisdomTree shares are bought and sold at market price (not NAV) and are not individually redeemed from the Fund. Total Returns are calculated using the daily 4:00pm EST net asset value (NAV). Market price returns reflect the midpoint of the bid/ask spread as of the close of trading on the exchange where Fund shares are listed. Market price returns do not represent the returns you would receive if you traded shares at other times.

## **Fund Dividend Distribution and Capital Gains**

Year	Income	Short-term Capital Gains	Long-term Capital Gains	Return of Capital	Year-End NAV
2024	0.00	0.00	0.00	0.00	N/A
2023	0.14	0.00	0.00	0.00	16.93
2022	0.07	0.00	0.00	0.00	17.28
2021	0.02	0.00	0.00	0.00	23.61



# WisdomTree BioRevolution Fund



may not total 100 due to rounding.

Top Fund Holdings	Weight	Top Fund Sector	Weight	Top Fund Country Breakdown	Weight
Iovance Biotherapeutics Inc	3.57%	Health Care	83.19%	United States	82.58%
Twist Bioscience Corp	3.06%	Materials	10.99%	Denmark	3.38%
Fate Therapeutics Inc	2.99%	Consumer Staples	3.67%	Germany	3.08%
Novozymes A/S	2.53%	Energy	2.16%	Switzerland	2.64%
Blueprint Medicines Corp	2.25%	Sectors may include many industries and weights are subject to change without notice.		United Kingdom	1.78%
Geron Corp	2.16%	weights are subject to chang	e without notice.	Netherlands	1.57%
Natera Inc	2.05%			Japan	1.21%
Vericel Corp	2.01%			Belgium	1.16%
Eli Lilly & Co	2.00%			Canada	0.83%
Bridgebio Pharma Inc	1.80%			Sweden	0.76%
Holdings are subject to change without notice.				Country allocations subject to char notice. Percentages for some of the charts	

#### **Disclosures**

Investors should carefully consider the investment objectives, risks, charges and expenses of the Fund before investing. For a prospectus or, if available, the summary prospectus containing this and other important information about the fund, call 866.909.9473 or visit WisdomTree.com/investments. Read the prospectus or, if available, the summary prospectus carefully before investing.

There are risks associated with investing, including possible loss of principal. The Fund invests in BioRevolution companies, which are companies significantly transformed by advancements in genetics and biotechnology. BioRevolution companies face intense competition and potentially rapid product obsolescence. These companies may be adversely affected by the loss or impairment of intellectual property rights and other proprietary information or changes in government regulations or policies. Additionally, BioRevolution companies may be subject to risks associated with genetic analysis. The Fund invests in the securities included in, or representative of, its Index regardless of their investment merit and the Fund does not attempt to outperform its Index or take defensive positions in declining markets. The composition of the Index is governed by an Index Committee and the Index may not perform as intended. Please read the Fund's prospectus for specific details regarding the Fund's risk profile.

The WisdomTree BioRevolution Index is designed to track performance of companies that will be significantly transformed by advancements in genetics and biotechnology that meet Index eligibility requirements.

The S&P 500 Health Care Index is a capitalization weighted index that measures the performance of the members of the GICS Healthcare sector within the S&P 500 Index.

The S&P Biotechnology Select Industry Index is designed to measure the performance of stocks from the S&P Total Market Index that are classified in the GICS biotechnology sub-industry.

Data Source: WisdomTree, S&P, Bloomberg.

WisdomTree Funds are distributed by Foreside Fund Services, LLC, in the U.S.

©2024 WisdomTree, Inc. "WisdomTree" and the company logo are registered trademarks of WisdomTree, Inc.

